APA

Galimberti S., Palumbo G. A., Caracciolo F., Benedetti E., Pelosini M., Brizzi S., Ciabatti E., Fazzi R., Stelitano C., Quintana G., Conte E., Tibullo D., Di Raimondo F. & Petrini M. (20071026). The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms. : Journal of chemotherapy (Florence, Italy).

Chicago

Galimberti S, Palumbo G A, Caracciolo F, Benedetti E, Pelosini M, Brizzi S, Ciabatti E, Fazzi R, Stelitano C, Quintana G, Conte E, Tibullo D, Di Raimondo F and Petrini M. 20071026. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms. : Journal of chemotherapy (Florence, Italy).

Harvard

Galimberti S., Palumbo G. A., Caracciolo F., Benedetti E., Pelosini M., Brizzi S., Ciabatti E., Fazzi R., Stelitano C., Quintana G., Conte E., Tibullo D., Di Raimondo F. and Petrini M. (20071026). The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms. : Journal of chemotherapy (Florence, Italy).

MLA

Galimberti S, Palumbo G A, Caracciolo F, Benedetti E, Pelosini M, Brizzi S, Ciabatti E, Fazzi R, Stelitano C, Quintana G, Conte E, Tibullo D, Di Raimondo F and Petrini M. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms. : Journal of chemotherapy (Florence, Italy). 20071026.